secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevance Health, Inc. (ELV)
CIK:        0001156039
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-205527
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elevance Health names Mark Kaye new CFO to succeed retiring John Gallina; reaffirms 2023 guidance
--------------------------------------------------------------------------------

- Mark Kaye appointed EVP and CFO effective Nov 1, 2023; will serve as CFO Designate starting Sep 6.
- John Gallina retiring after ~30 years at company; will remain as Special Advisor to CEO post-transition.
- Kaye's compensation: base salary $900k, target bonus 120% of base, LTI target $5.5M; one-time awards: $8M RSUs, $3.7M equity mix, and $2.5M cash.
- Kaye previously CFO at Moody's (2018-2023), held senior finance roles at MassMutual and Voya.
- Company reaffirms FY 2023 adjusted net income guidance > $32.85 per share; net income > $29.09 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1156039/000119312523205527/0001193125-23-205527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1156039/000119312523205527/d492032d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-205527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer